Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).

Norman A MazerCarsten HofmannDominik LottRonald GieschkeGregory KleinFrank BoessHans Peter GrimmGeoffrey A KerchnerMonika Baudler-KleinJanice SmithRachelle S Doodynull null

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2022)

A semi-mechanistic model was developed to link amyloid/tau/neurodegeneration biomarkers to clinical outcome (Q-ATN model). The Q-ATN model describes the disease progression seen in natural history studies. Model simulations agree well with mean data from the aducanumab EMERGE study. A 5-year simulation of gantenerumab predicts greater benefit with longer treatment.

Keyphrases

high resolution
machine learning
molecular dynamics
big data
cerebrospinal fluid